Imcyse SA
Geoffrey Gloire is currently serving as the IP & Innovation Director at Imcyse SA since October 2022. Prior to this role, Geoffrey held various positions at Imcyse S.A. from June 2016 to October 2022, starting as an IP Director and Early Projects Leader. Before joining Imcyse, Geoffrey worked as a Patent Advisor at Université de Liège (ULg) from October 2007 to April 2016. Geoffrey also has experience as a post-doctoral researcher at Inserm. Geoffrey obtained their PhD in Biochemistry and Molecular Biology from the University of Liège in 2001-2006 and has a Master's in Biological Sciences from the same university. Geoffrey's academic journey started at St Roch Ferrieres from 1991-1997.
Imcyse SA
Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases. The company’s unique technology platform can address a wide range of autoimmune and immunologic diseases. Imotopes™ are modified synthetic peptides, which specifically block improper immune activity. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no effective therapeutic alternative and has the potential to cure patients without impairing their immune defenses. Our vision is to become a leader in the field of active specific immunotherapy and to prevent, stop and potentially cure autoimmune diseases. Headquartered in Liège, Belgium, Imcyse was founded as a spin-off of the Catholic University of Leuven (KULeuven). Imcyse’s Imotope™ technology platform is protected by a robust, international intellectual property portfolio. Our lead Imotope™, IMCY-0098, is in phase 2 clinical testing for early onset type 1 diabetes.